G. Walmsley Graham

This profile gathers the share dealings of G. Walmsley Graham across 3 companies, led by Akero Therapeutics, Inc., Olema Pharmaceuticals, Inc. and ALX Oncology Holdings Inc. We count 29 filings; the first trade dates from 30 March 2020 and the latest from 9 December 2025.

In open-market terms, that means 16 purchases worth €88.6M on one side and 4 sales worth €28.1M on the other. On balance, insiders were net buyers of €60.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 2 option exercises. In 2025 alone, the filings show 2 purchases and no sales.

The median purchase comes to €4.2M. Clusters matter here: 3 out of 14 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +9.4%. This is a record of the past, not a forecast.

The record was last updated on 9 December 2025 with a transaction in Akero Therapeutics, Inc. The latest purchase dates back some time: it was published 591 days ago, on 27 March 2025. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.